Retrospective analysis of immune markers and BRAF status in melanoma patients: Implications for prognosis

Abstract

Dear Editor, Melanoma results from malignant melanocytic transformations following genetic mutagenesis post-ultraviolet (UV) exposure and is driven by specific genetic mutations (most commonly NF1, NRAS and BRAF mutations) and cumulative sun damage. BRAF mutations are frequently seen in low cumulative sun damage melanomas, which are more common than high cumulative sun damage melanomas. 1Targeted immunotherapy has emerged as a novel treatment option for melanoma. In particular, the combination of BRAF/MEK